Nebius Group prices $1 billion share offering at $92.50 per share
Investing.com - BofA Securities has reiterated its Buy rating and $230.00 price target on Ascendis Pharma (NASDAQ:ASND), naming it one of the firm’s top picks for 2025. The stock has shown remarkable momentum, delivering a 72.82% return over the past year and currently trading near its 52-week high of $207.
The recommendation comes as Ascendis’ Yorvipath global launch in hypoparathyroidism (HPT) shows strong initial results, with BofA expecting further acceleration as payor coverage expands. The company’s strong execution is reflected in its impressive 54.5% revenue growth over the last twelve months, maintaining a robust gross margin of 84.88%.
BofA believes Yorvipath is well-positioned to capture market share as the only marketed product in its category, with competing pipeline products reportedly several years behind in development.
The investment bank currently models $3.15 billion in peak sales for Yorvipath in HPT, which it calculates represents $147 per share in value.
BofA also sees additional upside potential from Ascendis expanding its Skytrofa label and possibly bringing a third asset to market with the upcoming November 30 PDUFA date for TransCon CNP in achondroplasia (ACH).
In other recent news, Ascendis Pharma announced its Q2 2025 earnings, showcasing a notable performance that exceeded analysts’ expectations. The company reported an earnings per share (EPS) of -0.82, which was a significant improvement compared to the forecasted -1.27, resulting in a surprise of 35.43%. Revenue figures also outperformed projections, coming in at €158 million, surpassing the anticipated €142.38 million by 11.01%. These results highlight Ascendis Pharma’s ability to deliver beyond market predictions. The earnings announcement marks a positive development for the company, reflecting its operational efficiency and strategic execution. This performance has been closely watched by investors and analysts alike, as it provides insights into the company’s financial health. While stock price movements were noted post-announcement, the focus remains on the earnings and revenue achievements. These recent developments underscore the importance of monitoring Ascendis Pharma’s financial disclosures for future investment considerations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.